Insmed raised its earnings forecast and outlined a path toward first-year BRINSUPRI sales and expanded indications for ARIKAYCE. Against the backdrop of third-quarter sales and a long-term outlook for profitability, the revision is expected to affect the market.
Insmed raised its earnings forecast for the current fiscal year. First-year sales of BRINSUPRI outside international markets are projected at $1.35 billion–$1.4 billion, while peak sales are expected to reach at least $7 billion. Third-quarter revenue was reported at $524.4 million, strengthening the basis for the company's outlook alongside the upward revision.
The company's long-term earnings outlook is based on analyst models projecting revenue of $4.4 billion and profit of $1.2 billion by 2029. The outlook assumes a shift from the current loss to profitability, with emphasis on achieving annual growth and positive cash flow over the next 3 years.
Near-term catalysts include the continued uptake of BRINSUPRI, a decision on expanding ARIKAYCE's indications, and plans to roll out consumer advertising. On the other hand, slower adoption among COPD and asthma patients and the risk of suspending the European rollout could undermine the ability to reach total sales targets. These factors could affect the path to profitability presented by management.
Some optimistic market views suggest that BRINSUPRI and ARIKAYCE could generate as much as $6 billion in sales and profit in 2029, while others say there is potential to substantially exceed consensus forecasts of $4.4 billion in revenue and $1.2 billion in profit. Future official announcements and earnings releases could affect this view.